Vaxcyte (PCVX) Assets (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Assets data on file, last reported at $3.3 billion in Q1 2026.

• Assets for Q1 2026 came in at $3.3 billion, down 0.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.3 billion (down 0.88% YoY), and the FY2025 annual result was $3.0 billion, down 14.48% from the prior year.
• Assets advanced to $3.3 billion in Q1 2026 per PCVX's latest filing, from $3.0 billion in the prior quarter.
• Over five years, Assets peaked at $3.6 billion in Q3 2024 and troughed at $402.7 million in Q1 2022.
• A 5-year average of $2.1 billion and a median of $2.1 billion in 2024 frame the typical range for Assets.
• The sharpest annual moves came in 2023 and 2025: Assets jumped 265.1% in 2023, then decreased 14.48% in 2025.
• A 5-year view of Assets shows it stood at $1.0 billion in 2022, then soared by 39.93% to $1.4 billion in 2023, then surged by 149.4% to $3.5 billion in 2024, then declined by 14.48% to $3.0 billion in 2025, then grew by 11.51% to $3.3 billion in 2026.
• Business Quant data shows PCVX's Assets at $3.3 billion in Q1 2026, $3.0 billion in Q4 2025, and $3.2 billion in Q3 2025.